Abscess – Pipeline Review, H2 2011

Document Sample
Abscess – Pipeline Review, H2 2011 Powered By Docstoc
					Abscess – Pipeline Review, H2 2011




                               Abscess – Pipeline Review, H2 2011


                                                                                          Reference Code: GMDHC1616IDB
                                                                                          Publication Date: December 2011




Abscess – Pipeline Review, H2 2011                                                        GMDHC1616IDB / Pub December 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                            Page(1)
Abscess – Pipeline Review, H2 2011




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 4
    List of Figures ................................................................................................................................................................................ 4
Introduction......................................................................................................................................................................................... 5
    Global Markets Direct Report Coverage ........................................................................................................................................ 5
Abscess Overview .............................................................................................................................................................................. 6
Therapeutics Development................................................................................................................................................................. 7
    An Overview of Pipeline Products for Abscess .............................................................................................................................. 7
Abscess Therapeutics under Development by Companies ................................................................................................................ 9
Abscess Therapeutics under Investigation by Universities/Institutes ............................................................................................... 10
Late Stage Products ......................................................................................................................................................................... 11
    Comparative Analysis .................................................................................................................................................................. 11
Mid Clinical Stage Products.............................................................................................................................................................. 12
    Comparative Analysis .................................................................................................................................................................. 12
Abscess Therapeutics – Products under Development by Companies ............................................................................................ 13
Abscess Therapeutics – Products under Investigation by Universities/Institutes ............................................................................. 14
Companies Involved in Abscess Therapeutics Development ........................................................................................................... 15
    Johnson & Johnson ..................................................................................................................................................................... 15
    Rib-X Pharmaceuticals, Inc. ........................................................................................................................................................ 16
    Taiho Pharmaceutical Co., Ltd. ................................................................................................................................................... 17
    Durata Therapeutics Inc. ............................................................................................................................................................. 18
Abscess – Therapeutics Assessment............................................................................................................................................... 19
    Assessment by Monotherapy Products ....................................................................................................................................... 19
    Assessment by Combination Products ........................................................................................................................................ 20
    Assessment by Route of Administration ...................................................................................................................................... 21
    Assessment by Molecule Type .................................................................................................................................................... 23
Drug Profiles..................................................................................................................................................................................... 25
    Dalbavancin - Drug Profile ........................................................................................................................................................... 25
         Product Description................................................................................................................................................................. 25
         Mechanism of Action ............................................................................................................................................................... 25
         R&D Progress ......................................................................................................................................................................... 25
    RX-1741 - Drug Profile ................................................................................................................................................................ 27
         Product Description................................................................................................................................................................. 27
         Mechanism of Action ............................................................................................................................................................... 27
         R&D Progress ......................................................................................................................................................................... 27
    Oritavancin - Drug Profile ............................................................................................................................................................ 29
         Product Description................................................................................................................................................................. 29
         Mechanism of Action ............................................................................................................................................................... 29
         R&D Progress ......................................................................................................................................................................... 29
    Tissue Plasminogen Activator - Drug Profile ............................................................................................................................... 31
         Product Description................................................................................................................................................................. 31
         Mechanism of Action ............................................................................................................................................................... 31



Abscess – Pipeline Review, H2 2011                                                                                                        GMDHC1616IDB / Pub December 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Abscess – Pipeline Review, H2 2011



         R&D Progress ......................................................................................................................................................................... 31
    JNJ-Q2 - Drug Profile .................................................................................................................................................................. 32
         Product Description................................................................................................................................................................. 32
         Mechanism of Action ............................................................................................................................................................... 32
         R&D Progress ......................................................................................................................................................................... 32
    Pasireotide - Drug Profile ............................................................................................................................................................ 34
         Product Description................................................................................................................................................................. 34
         Mechanism of Action ............................................................................................................................................................... 34
         R&D Progress ......................................................................................................................................................................... 34
    Moxifloxacin + Metronidazole - Drug Profile ................................................................................................................................ 35
         Product Description................................................................................................................................................................. 35
         Mechanism of Action ............................................................................................................................................................... 35
         R&D Progress ......................................................................................................................................................................... 35
    Trimethoprim + Sulfamethoxazole + Clindamycin - Drug Profile ............
				
DOCUMENT INFO
Description: Abscess – Pipeline Review, H2 2011 Summary Global Markets Direct’s, 'Abscess - Pipeline Review, H2 2011', provides an overview of the Abscess therapeutic pipeline. This report provides information on the therapeutic development for Abscess, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Abscess. 'Abscess - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Abscess. - A review of the Abscess products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Abscess pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Abscess. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by
BUY THIS DOCUMENT NOW PRICE: $500 100% MONEY BACK GUARANTEED
PARTNER GlobalMarketsDirect
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. Global Markets Direct has a broad range of coverage over key market segments. It has a global scope, covering a broad range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries